Genetic variation in ABCB1 influences paclitaxel pharmacokinetics in Japanese patients with ovarian cancer

International Journal of Gynecological Cancer

Volumn 16, Issue 3, 2006, Pages 979-985

  Yamaguchi, H ^a,b   Hishinuma, T ^a,b   Endo, N ^a   Tsukamoto, H ^a,e   Kishikawa, Y ^b   Sato, M ^b   Murai, Y ^b   Hiratsuka, M ^c   Ito, K ^d   Okamura, C ^d   Yaegashi, N ^d   Suzuki, N ^a,b,f   Tomioka, Y ^a,b   Goto, J ^a,b  

^a TOHOKU UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY HOSPITAL   (Japan)

^c TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

^d TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e JUNTENDO UNIVERSITY   (Japan)

^f JOSAI INTERNATIONAL UNIVERSITY   (Japan)

Author keywords

ABCB1; Genetic polymorphisms; Ovarian cancer; Paclitaxel pharmacokinetics

Indexed keywords

ABC TRANSPORTER A1; ANTINEOPLASTIC AGENT; CYTOCHROME P450 2C8; CYTOCHROME P450 3A4; DRUG METABOLITE; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PREGNANE X RECEPTOR;

ADULT; AGED; ALLELE; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; JAPAN; METABOLITE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DRUG RESISTANCE, NEOPLASM; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; JAPAN; MAXIMUM TOLERATED DOSE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; ORGANIC ANION TRANSPORTERS; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; PACLITAXEL; RECEPTORS, STEROID; STATISTICS; STATISTICS AS TOPIC; VARIATION (GENETICS);

EID: 33745092788     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00593.x     Document Type: Article

References (30)

1. Rowinsky EK. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med 1997 48 : 353 74.
2. Wiernik PH Schwartz EL Strauman JJ Dutcher JP Lipton RB Paietta E. Phase I clinical and pharmacokinetic study of taxol. Cancer Res 1987 47 : 2486 93.
3. Brown T Havlin K Weiss G et al. A phase I trial of taxol given by a 6-hour intravenous infusion. J Clin Oncol 1991 9 : 1261 7.
4. Grem JL Tutsch KD Simon KJ et al. Phase I study of taxol administered as a short i.v. infusion daily for 5 days. Cancer Treat Rep 1987 71 : 1179 84.
5. Longnecker SM Donehower RC Cates AE et al. High-performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial. Cancer Treat Rep 1987 71 : 53 9.
6. Walle T Walle UK Kumar GN Bhalla KN. Taxol metabolism and disposition in cancer patients. Drug Metab Dispos 1995 23 : 506 12.
7. Cresteil T Monsarrat B Alvinerie P Treluyer JM Vieira I Wright M. Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res 1994 54 : 386 92.
8. Rahman A Korzekwa KR Grogan J Gonzalez FJ Harris JW. Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 1994 54 : 5543 6.
9. Harris JW Rahman A Kim BR Guengerich FP Collins JM. Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res 1994 54 : 4026 35.
10. Kuehl P Zhang J Lin Y et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001 27 : 383 91.
11. Bradley G Ling V. P-glycoprotein, multidrug resistance and tumor progression. Cancer Metastasis Rev 1994 13 : 223 33.
12. Gottesman MM Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993 62 : 385 427.
13. Thiebaut F Tsuruo T Hamada H Gottesman MM Pastan I Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 1987 84 : 7735 8.
14. Xie W Evans RM. Orphan nuclear receptors: the exotics of xenobiotics. J Biol Chem 2001 276 : 37739 42.
15. Bahadur N Leathart JB Mutch E et al. CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes. Biochem Pharmacol 2002 64 : 1579 89.
16. Dai D Zeldin DC Blaisdell JA et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 2001 11 : 597 607.
17. Tanabe M Ieiri I Nagata N et al. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 2001 297 : 1137 43.
18. Hiratsuka M Agatsuma Y Mizugaki M. Rapid detection of CYP2C9*3 alleles by real-time fluorescence PCR based on SYBR Green. Mol Genet Metab 1999 68 : 357 62.
19. Jamis-Dow CA Klecker RW Sarosy G Reed E Collins JM. Steady-state plasma concentrations and effects of taxol for a 250 mg/m2 dose in combination with granulocyte-colony stimulating factor in patients with ovarian cancer. Cancer Chemother Pharmacol 1993 33 : 48 52.
20. Yamaoka K Nakagawa T Uno T. Statistical moments in pharmacokinetics. J Pharmacokinet Biopharm 1978 6 : 547 58.
21. Zhang J Kuehl P Green ED et al. The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics 2001 11 : 555 72.
22. Nakajima M Fujiki Y Noda K et al. Genetic polymorphisms of CYP2C8 in Japanese population. Drug Metab Dispos 2003 31 : 687 90.
23. Soyama A Saito Y Hanioka N et al. Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism. Biol Pharm Bull 2001 24 : 1427 30.
24. Niemi M Leathart JB Neuvonen M Backman JT Daly AK Neuvonen PJ. Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. Clin Pharmacol Ther 2003 74 : 380 7.
25. Fukuen S Fukuda T Maune H et al. Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population. Pharmacogenetics 2002 12 : 331 4.
26. Mathijssen RH Marsh S Karlsson MO et al. Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res 2003 9 : 3246 53.
27. Kim RB Leake BF Choo EF et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001 70 : 189 99.
28. Hoffmeyer S Burk O von Richter O et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000 97 : 3473 8.
29. Nakajima M Fujiki Y Kyo S et al. Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1. J Clin Pharmacol 2005 45 : 674 82.
30. Penson RT Oliva E Skates SJ et al. Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Gynecol Oncol 2004 93 : 98 106.